Last updated: May 30, 2026
PANRETIN drug suppliers (API, finished-dose manufacturers, and key distributors)
Panretin is a branded topical retinoid product. Supplier identification for Panretin is split across three layers that drive procurement risk: (1) active pharmaceutical ingredient (API) sources, (2) finished-dose (tube/packaged product) manufacturing sites, and (3) distribution partners used for hospital and retail fulfillment.
Insufficient sourcing data is available in the provided input to name specific API suppliers, finished-dose manufacturers, or distributor companies for Panretin.
Which companies supply Panretin (finished product and distribution)?
Answer: Not determinable from the provided information.
Finished-dose manufacturing and packaging entities
Answer: Not determinable from the provided information.
Wholesalers and distribution partners
Answer: Not determinable from the provided information.
What API suppliers make Panretin active ingredient (alitretinoin)
Answer: Not determinable from the provided information.
API suppliers by retinoid category
Answer: Not determinable from the provided information.
API sourcing risks (quality, GMP, traceability)
Answer: Not determinable from the provided information.
What is the supply chain for PANRETIN in the US (NDC holders, manufacturers, distributors)?
Answer: Not determinable from the provided information.
Orange Book / FDA listing tie to manufacturing plants
Answer: Not determinable from the provided information.
NDC labeler vs. manufacturer vs. distributor
Answer: Not determinable from the provided information.
Who are the contract manufacturers for Panretin tubes and cartons?
Answer: Not determinable from the provided information.
Packaging line requirements for topical retinoids
Answer: Not determinable from the provided information.
Sterility is not the driver, but exposure control is
Answer: Not determinable from the provided information.
How many suppliers exist for Panretin (single vs. multiple sources)?
Answer: Not determinable from the provided information.
Redundancy in API and finished-dose manufacturing
Answer: Not determinable from the provided information.
Alternative sourcing for manufacturing interruption continuity
Answer: Not determinable from the provided information.
What generic or competitor products indicate alternative supplier capacity?
Answer: Not determinable from the provided information.
Cross-sourcing via same API (other topical retinoids)
Answer: Not determinable from the provided information.
What regulatory filings identify Panretin’s manufacturing sites (site names, responsible parties)?
Answer: Not determinable from the provided information.
Labeling and FDA administrative data points
Answer: Not determinable from the provided information.
What procurement documents typically list Panretin suppliers?
Answer: Not determinable from the provided information.
Sources procurement teams use
Answer: Not determinable from the provided information.
Key Takeaways
- Panretin supplier mapping requires FDA/NDC labeler-to-manufacturer and/or application-level manufacturing site data plus API vendor sourcing.
- The provided input does not include the required identifiers to name specific Panretin suppliers.
FAQs
- Which entity is the NDC labeler for Panretin?
- Who manufactures Panretin finished dose in the US?
- What are the API sources for the active ingredient used in Panretin?
- Are there alternative manufacturers for Panretin tubes to mitigate supply disruption?
- Which wholesalers distribute Panretin to US accounts?
References
- No citable sources were provided in the prompt.
